Hims & Hers Lands Eli Lilly's GLP-1s at $149 a Month, Drops Compounded Copies
As seen on the 24/7 Wall St. homepage on November 11, 2026.
Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
Hims & Hers just landed Eli Lilly's branded GLP-1s on its platform, with self-pay pricing starting at $149 a month for Foundayo, and it agreed to stop offering compounded copies of Lilly's drugs. That swaps a legally shaky revenue stream for an authorized supply deal with the category leader.
Continue ReadingShow less
Hims & Hers has struck a distribution agreement with Eli Lilly to offer two of Lilly's branded GLP-1 medicines directly through its platform. Eligible patients who get a prescription from a licensed provider can have Foundayo (orforglipron) shipped to their door for $149 a month, or Zepbound (tirzepatide) for $299 a month, with no insurance required.
As part of the deal, Hims & Hers has committed to stop offering compounded copies of Lilly's GLP-1 medicines. Compounded versions had occupied a legal grey zone, and that revenue stream now gives way to an authorized supply arrangement with the category's dominant manufacturer.
The deal trades volume that depended on a regulatory exception for a formal relationship with Lilly. Patients move through the full Hims & Hers funnel, completing a consultation and receiving a prescription if appropriate, but the medicine they receive is FDA-approved and Lilly-sourced.
Sponsored
Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities, said the company is 'always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are.' Andrew Dudum, co-founder and CEO of Hims & Hers, said the two companies are 'showing the industry what innovators can achieve for customers everywhere when we work together to make the world well.'
The broader market backdrop on November 11, 2026, was constructive: the Nasdaq Composite rose 2.06% on the session, with the S&P 500 also higher. Volatility eased alongside those gains.
